Ironwood Pharmaceuticals Inc - Company Profile
Powered by 
All the data and insights you need on Ironwood Pharmaceuticals Inc in one report.
$295
- Save hours of research time and resources with
our up-to-date Ironwood Pharmaceuticals Inc Strategy Report
- Understand Ironwood Pharmaceuticals Inc position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
Ironwood Pharmaceuticals Inc (Ironwood) is a healthcare company engaged in the discovery, development and commercialization of human therapeutics and innovative gastrointestinal product opportunities. The company’s pipeline products include linaclotide, and vascular or fibrotic programs. Ironwood offers its products under two brands- Linzess and Constella. The company generates a pipeline of early development candidates and discovery research programs in various therapeutic areas which include gastrointestinal (GI), central nervous system (CNS) and allergic disorders. The company’s portfolio includes CNP-104, CNP-104 and IW-3300. It has strategic partnerships with leading pharmaceutical companies such as AbbVie Inc, for the development and commercialization of linaclotide across the globe. The company operates in the US and Switzerland. Ironwood is headquartered in Boston, Massachusetts, the US.
Headquarters
United States of America
Address
100 Summer Street, Suite 2300, Boston, Massachusetts, 02110
Website
www.ironwoodpharma.com
Telephone
1 617 6217722
No of Employees
267
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
IRWD (NASD)
Revenue (2022)
$442.7M
7.8%
(2022 vs 2021)
EPS
XYZ
Net Income (2022)
XYZ
-672.5%
(2022 vs 2021)
Market Cap*
$1.2B
Net Profit Margin (2022)
XYZ
-630.9%
(2022 vs 2021)
* As of and is in US$
Ironwood Pharmaceuticals Inc premium industry data and analytics
Products and Services
| Products | Brands |
|---|---|
| IW-3300- Chronic Visceral Pain | Linzess |
| CNP-104 - Rare Autoimmune | Constella |
| Marketed | |
| XYZ | |
| XYZ | |
| XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2023 | Regulatory Approval | In June, the company secured approval from U.S. Food and Drug Administration for LINZESS (linaclotide) to treat pediatric patients ages 6-17 years-old with functional constipation. |
| 2023 | Acquisitions/Mergers/Takeovers | In June, the company acquired VectivBio Holding AG. |
| 2023 | Regulatory Approval | In February, the company announced that the U.S. Food and Drug Administration granted priority review to the supplemental New Drug Application (sNDA) for LINZESS (linaclotide) for the treatment of children and adolescents ages 6-17 years-old with functional constipation. |
Competitor Comparison
| Key Parameters | Ironwood Pharmaceuticals Inc | Takeda Pharmaceutical Co Ltd | Viatris Inc | Bausch Health Companies Inc | Endo International Plc |
|---|---|---|---|---|---|
| Headquarters | United States of America | Japan | United States of America | Canada | Ireland |
| City | Boston | Chuo-Ku | Canonsburg | Laval | Dublin |
| State/Province | Massachusetts | Tokyo | Pennsylvania | Quebec | - |
| No. of Employees | 267 | 49,095 | 38,000 | 20,270 | 2,931 |
| Entity Type | Public | Public | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Julie H. McHugh | Chairman | Executive Board | 2019 | 58 |
| Thomas McCourt | Chief Executive Officer; Director | Executive Board | 2021 | 65 |
| Sravan K. Emany | Senior Vice President; Chief Financial Officer | Senior Management | 2021 | 45 |
| John Minardo | Secretary; Senior Vice President; Chief Legal Officer | Senior Management | 2021 | 47 |
| Michael Shetzline, M.D., Ph.D. | Head - Research and Development; Senior Vice President; Chief Medical Officer | Senior Management | 2021 | 63 |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward